EVALUATION OF THE USE OF HEPATOPROTECTORSIN PATIENTS WITH CHRONIC VIRAL HEPATITIS B.

dc.contributor.author	Yakubova Nigina Sadriddinovna
dc.date.accessioned	2025-12-29T17:56:36Z
dc.date.issued	2024-10-26
dc.description.abstract	According to WHO data, over the past 20 years, there has been a trend towards an increase in the number of liver diseases that cause high mortality in the population [3]. 107 patients diagnosed with CHB were under observation. All patients underwent a method for quantitative determination of HBV viral load by PCR. The level of liver fibrosis was also determined by a non-invasive method - fibroscanning. As a hepatoprotective therapy, patients were prescribed.
dc.format	application/pdf
dc.identifier.uri	https://webofjournals.com/index.php/5/article/view/1981
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/24107
dc.language.iso	eng
dc.publisher	Web of Journals Publishing
dc.relation	https://webofjournals.com/index.php/5/article/view/1981/1959
dc.rights	https://creativecommons.org/licenses/by-nc-nd/4.0
dc.source	Web of Medicine: Journal of Medicine, Practice and Nursing ; Vol. 2 No. 10 (2024): WOM; 150-153
dc.source	2938-3765
dc.title	EVALUATION OF THE USE OF HEPATOPROTECTORSIN PATIENTS WITH CHRONIC VIRAL HEPATITIS B.
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: sadriddinovna_2024_evaluation_of_the_use_of_hepatoprotector.pdf
item.page.filesection.size: 268.75 KB
item.page.filesection.format: Adobe Portable Document Format